versão On-line ISSN 2078-5135
SAMJ, S. Afr. med. j. vol.98 no.10 Cape Town Out. 2008
Katharine A Robertson; Bongani M Mayosi
Department of Medicine University of Cape Town and Groote Schuur Hospital Cape Town
Rheumatic fever (RF) and rheumatic heart disease (RHD) are primarily diseases of childhood and young adulthood. As a result of this epidemiological pattern, RF and RHD negatively impact on society by decreasing the capacity of the most productive age groups, as well as limiting future capacity by thwarting the development of young people. Acute RF and RHD lead to increased school absenteeism and drop-out, and lost wages due to parental absenteeism from work. The patient and the family bear most of the brunt of these costs, which are shared to some extent by society as a whole.
The global burden of RF and RHD over the past century has shifted to fall almost entirely on people living in the developing world, who constitute 80% of the world population. The worldwide prevalence of RHD is estimated at 15.6 million, with 282 000 new cases arising each year, resulting in 233 000 deaths per year.1 Ninety-five per cent of these cases and deaths occur in the developing world. Sub-Saharan Africa has the highest average prevalence of RHD of 30 per 1 000 schoolchildren, leading to the designation of this region as the 'hotspot' of RF and RHD in the world.2 This geographical distribution of disease highlights the link of RF and RHD with poverty. RF and RHD are not only the result of conditions that exist in poverty; they also act to perpetuate poverty by crippling a significant proportion of the most productive members of society, thereby hindering economic growth. Understanding and defining the relationship between RF/ RHD and poverty is an important step in building the political support, national and international, to fashion and implement a plan of action to combat the disease.
What is the socio-economic impact of RF and RHD?
At least two studies from Brazil and India have attempted to quantify the socio-economic impact of RF and RHD.3,4 The Brazilian study provides a useful breakdown of direct and indirect costs that impact on the patient, family and society.3 Direct costs to the family include medical consultations, laboratory tests, transportation, and lost wages. Assuming that most patients with RF/RHD receive publicly funded health care, direct costs to society include medical consultations not paid for by the family, hospital admissions, cardiac catheterisation and surgical costs, and medications and laboratory tests. Indirect costs to the family include lost wages because of work missed, while indirect costs to society encompass the production losses attributable to lost workdays. While these costs associated with RF and RHD are not exhaustive, they include most of the pertinent tangible costs. In Sao Paulo, Brazil, RF costs the affected patient and family about US$97/patient/year, and the disease costs society US$320/patient/year. The annual cost of a secondary prevention programme is US$23/patient/year in Brazil. Compared with the cost burden on the family or the society for treating a case of RF, this analysis clearly confirms that secondary prevention is a cost-effective intervention.
The Indian study sets out to compare the cost-effectiveness of primary, secondary and tertiary prevention programmes for RF/RHD.4 The investigators compared the input cost vs. the output cost for each form of prevention strategy. They found that primary and secondary prevention are both cost-effective interventions and while primary prevention is more expensive to implement, the outputs, or economic/social gains, of primary prevention exceed both secondary and tertiary gains. They also found that tertiary prevention (i.e. medical and surgical intervention for heart failure due to RHD) is least cost-effective. While this study has been criticised on methodological grounds,5 it highlights the fact that leaving the disease untreated increases the economic cost to the patient, family and society.
In addition to tangible economic losses associated with RF/RHD, there are also intangible costs, or social implications that cannot be quantified. Patients disabled by RHD often face physical limitations, which can restrict their future educational and work opportunities. The Brazilian study found that children affected by RF/RHD have a 22% school failure rate, which can further limit future career options. And with respect to their parents, 5% reported losing their jobs because of absenteeism associated with the illness of their child.
What are the prospects for the eradication of RF and RHD?
The developing world faces a double burden of infectious diseases, which are associated with poverty, and chronic diseases associated with urbanisation and social change. RF and RHD comprise a unique disease entity that spans the infectious and post-infectious chronic disease paradigm. The antecedent stage of streptococcal pharyngitis is infectious, relatively simple to diagnose and inexpensive to treat.6 As the disease progresses towards the chronic stage (RHD), it becomes expensive for the patient, the family and the society to diagnose and to treat by medical and surgical means.
It has been amply demonstrated in Cuba, Costa Rica and other countries that a comprehensive strategy of primary prevention (i.e. syndromic treatment of suspected 'strep' pharyngitis with penicillin), secondary prevention (screening for rheumatic heart disease in schoolchildren and use of penicillin prophylaxis for affected children), and tertiary prevention (i.e. medical and surgical treatment of patients with heart failure due to RHD) results in almost complete eradication of the disease within 10 - 20 years.7,8
The Drakensberg Declaration of the Pan African Society of Cardiology (PASCAR) calls on national ministries of health in Africa to adopt the A.S.A.P. Programme for the prevention of RF and RHD. This programme seeks to emulate the Cuban and Costa Rican examples through the application of evidence-based approaches to the prevention of the disease on national and continental levels.9,10 The occasion of national Rheumatic Fever Week, which was marked by the Minister of Health on 4 - 8 August 2008, provided us with an opportunity to rededicate ourselves to the fight for the eradication of RF and RHD ... 'in our own lifetime'.11
1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5: 685-694. [ Links ]
2. Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiography screening. N Engl J Med 2007; 357: 470-476. [ Links ]
3. Terreri MT, Ferraz MB, Goldenberg J, Len C, Hilário MO. Resource utilization and cost of rheumatic fever. J Rheumatol 2001; 28: 1394-1397. [ Links ]
4. Soudarssanane MB, Karthigeyan M, Mahalakshmy T, et al. Rheumatic fever and rheumatic heart disease: Primary prevention is the cost effective option. Indian J Pediatr 2007; 74: 567-570. [ Links ]
5. Irlam J, Mayosi BM, Gaziano T. Rheumatic fever and rheumatic heart disease: primary prevention in the cost effective option. Indian J Pediatr 2008; 75: 86. [ Links ]
6. Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord 2005; 5: 11. [ Links ]
7. Nordet P, Lopez R, Duenas A, Sarmento L. Prevention and control of rheumatic fever and rheumatic heart disease: the Cuban experience (1986-1996-2002). Cardiovasc J Afr 2008; 19: 135-140. [ Links ]
8. Arguedas A, Mohs E. Prevention of rheumatic fever in Costa Rica. J Pediatr 1992; 121: 569-572. [ Links ]
9. Mayosi BM, Robertson K, Volmink J, et al. The Drakensberg declaration on the control of rheumatic fever and rheumatic heart disease in Africa. S Afr Med J 2006; 96: 246. [ Links ]
10. Robertson KA, Volmink JA, Mayosi BM. Towards a uniform plan for the control of rheumatic fever and rheumatic heart disease in Africa - the Awareness Surveillance Advocacy Prevention (A.S.A.P.) Programme. S Afr Med J 2006; 96: 241. [ Links ]
11. Mayosi BM. A proposal for the eradication of rheumatic fever in our lifetime. S Afr Med J 2006; 96: 229-230. [ Links ]
B M Mayosi